Skip to main content

Table 4 Odds ratios for risk of worsening or improvement in EQ-5D anxiety/depression dimension when pain/discomfort dimension worsens or improves, respectively (not by treatment)

From: Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial

  Odds ratio (95% CI)
Week 13 (n = 1403) Week 25 (n = 1087) Week 37 (n = 914) Week 49 (n = 770) Week 61 (n = 625)
Worsening of Anxiety/Depression with worsening Pain/Discomfort 2.495 (1.749–3.559) 3.623 (2.426–5.410) 2.259 (1.431–3.564) 2.696 (1.690–4.303) 1.457 (0.832–2.554)
Improvement in Anxiety/Depression with improvement in Pain/Discomfort 2.514 (1.591–3.972) 1.890 (1.159–3.083) 2.937 (1.738–4.964) 2.916 (1.643–5.177) 2.789 (1.380–5.638)
  1. CI confidence interval